scispace - formally typeset
D

David Cameron

Researcher at University of Oslo

Publications -  1765
Citations -  141776

David Cameron is an academic researcher from University of Oslo. The author has contributed to research in topics: Large Hadron Collider & Breast cancer. The author has an hindex of 154, co-authored 1586 publications receiving 126067 citations. Previous affiliations of David Cameron include Universidade Nova de Lisboa & Cameron International.

Papers
More filters
Journal ArticleDOI

Phase III Study Comparing Exemestane With Tamoxifen As First-Line Hormonal Treatment of Metastatic Breast Cancer in Postmenopausal Women: The European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group

Robert Paridaens, +8 more
- 20 Oct 2008 - 
TL;DR: Exemestane is an effective and well-tolerated first-line hormonal treatment for postmenopausal women with MBC and offers significant early improvement in time to tumor progression when compared with tamoxifen.
Journal ArticleDOI

Performance of missing transverse momentum reconstruction in proton-proton collisions at√s = 7 TeV with atlas

Georges Aad, +5562 more
- 01 Jan 2012 - 
TL;DR: In this paper, the performance of the missing transverse momentum reconstruction was evaluated using data collected in pp collisions at a centre-of-mass energy of 7 TeV in 2010.
Journal ArticleDOI

Luminosity determination in pp collisions at √s = 8 TeV using the ATLAS detector at the LHC

Morad Aaboud, +2872 more
- 13 Aug 2016 - 
TL;DR: The luminosity determination for the ATLAS detector at the LHC during pp collisions at s√= 8 TeV in 2012 is presented in this article, where the evaluation of the luminosity scale is performed using several luminometers.
Journal ArticleDOI

Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer

David Miles, +158 more
- 01 Jul 2021 - 
TL;DR: In the phase III IMpassion130 trial, combining atezolizumab with first-line nanoparticle albumin-bound-paclitaxel for advanced triple-negative breast cancer (aTNBC) showed a statistically significant progression-free survival (PFS) benefit in the intention-to-treat (ITT) and programmed death-ligand 1 (PD-L1)-positive populations, and a clinically meaningful overall survival (OS) effect in PD-L 1-positive aTNBC as discussed by the authors.
Journal ArticleDOI

Intracranial efficacy and survival with tucatinib plus trastuzumab and capecitabine for previously treated HER2-positive breast cancer with brain metastases in the HER2CLIMB trial

Nan Lin, +28 more
- 29 May 2020 - 
TL;DR: In patients with HER2-positive breast cancer with BMs, the addition of tucatinib to trastuzumab and capecitabine doubled ORR-IC, reduced risk of intracranial progression or death by two thirds, and reduced riskof death by nearly half.